<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37101" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Doxylamine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brott</surname>
            <given-names>Nathan R.</given-names>
          </name>
          <aff>University of Tennessee HSC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reddivari</surname>
            <given-names>Anil Kumar Reddy</given-names>
          </name>
          <aff>University of Illinois</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nathan Brott declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anil Kumar Reddy Reddivari declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37101.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Doxylamine is a medication used to manage and treat nausea and vomiting of pregnancy (NVP), allergic rhinitis, and insomnia. It is in the first-generation histamine receptor H1 antagonist class of medications. In the USA, it is available as an over-the-counter medication. This activity reviews the indications, action, and contraindications for doxylamine as a valuable agent in managing nausea and vomiting of pregnancy (NVP), allergic rhinitis, and insomnia.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of doxylamine.</p></list-item><list-item><p>Describe the potential adverse effects of doxylamine.</p></list-item><list-item><p>Summarize the indications for doxylamine use.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance doxylamine and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37101&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37101">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-37101.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Doxylamine succinate with pyridoxine has approval from the U.S. Food and Drug Administration for the first-line treatment of&#x000a0;nausea and vomiting&#x000a0;of pregnancy (NVP).<xref ref-type="bibr" rid="article-37101.r1">[1]</xref>&#x000a0; Nausea&#x000a0;and vomiting&#x000a0;of pregnancy affects up to 85% of women during pregnancy&#x02014;it is the most prevalent medical condition during pregnancy.<xref ref-type="bibr" rid="article-37101.r2">[2]</xref> Most patients with NVP are manageable by making alterations to diet and lifestyle factors; however, more than 30% might need fluids, vitamin supplementation, and&#x000a0;additional treatment with an antiemetic such as doxylamine.<xref ref-type="bibr" rid="article-37101.r3">[3]</xref></p>
        <p>Like other antihistamines, it is also&#x000a0;indicated for the management of allergic rhinitis.<xref ref-type="bibr" rid="article-37101.r4">[4]</xref> Allergic rhinitis is the most prevalent atopic disorder, and symptoms consist of nasal congestion, sneezing, rhinorrhea, and nasal itching.<xref ref-type="bibr" rid="article-37101.r5">[5]</xref> Doxylamine tablets are also available over-the-counter as an approved sleep aid for insomnia in the USA.<xref ref-type="bibr" rid="article-37101.r6">[6]</xref> Insomnia is among the most commonly encountered patient concerns, and it can have significant adverse effects on mental and physical health.<xref ref-type="bibr" rid="article-37101.r7">[7]</xref></p>
      </sec>
      <sec id="article-37101.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>As a member of the&#x000a0;first-generation class of antihistamines, doxylamine exerts its effects by competitively antagonizing the binding of free histamine at the H1-receptor binding sites. It antagonizes&#x000a0;the effects of histamine in the uterus, GI tract, large blood vessels, and bronchial muscles. Doxylamine binds non-selectively to H1-receptors, both centrally and peripherally, contributing to the sedative effects&#x000a0;that also make it an effective&#x000a0;sleeping aid. However, due to&#x000a0;their interactions with receptor residues that remain highly conserved across the aminergic receptors, H1 receptor antagonists can produce several off-target effects; these are anticholinergic. This activity also depresses labyrinthine function, blocks the chemoreceptor trigger zone, and diminishes vestibular stimulation.<xref ref-type="bibr" rid="article-37101.r8">[8]</xref></p>
        <p>Furthermore,&#x000a0;doxylamine reduces nausea and vomiting by inhibiting histaminergic signaling to the vomiting center in the medulla.<xref ref-type="bibr" rid="article-37101.r9">[9]</xref>&#x000a0;The mechanism of action of pyridoxine while treating nausea and vomiting during pregnancy is unknown.</p>
        <p>The drug undergoes extensive hepatic metabolism and is excreted primarily in the urine. It has a half-life of approximately 10 hours, which increases to 12 to 15 hours in the elderly.</p>
      </sec>
      <sec id="article-37101.s4" sec-type="Administration">
        <title>Administration</title>
        <p>To treat nausea and vomiting during pregnancy, doxylamine is often co-administered with pyridoxine (vitamin B6)&#x000a0;as an extended-release oral tablet (doxylamine succinate 10 mg/ pyridoxine-HCl 10 mg). The tablets should not be crushed, chewed, or split to&#x000a0;maintain the extended-release effects.<xref ref-type="bibr" rid="article-37101.r10">[10]</xref>&#x000a0;For NVP, the recommended dose is two tablets before bed with water on an empty stomach. If symptoms&#x000a0;continue on the second day, the patient can take one tablet after waking in the morning&#x000a0;and two at night. If symptoms&#x000a0;remain inadequately controlled with a three tablet regimen on the third day, the dose could increase to four tablets&#x000a0;per day: one in the morning, one mid-afternoon, and two before bed. The maximum daily limit is four tablets.</p>
        <p>Patients should not take doxylamine/pyridoxine as needed while treating NVP.&#x000a0;The need for continued therapy requires reassessment throughout the pregnancy.<xref ref-type="bibr" rid="article-37101.r11">[11]</xref><xref ref-type="bibr" rid="article-37101.r12">[12]</xref><xref ref-type="bibr" rid="article-37101.r13">[13]</xref>&#x000a0;</p>
        <p>Doxylamine as a standalone medication&#x000a0;is also available as doxylamine succinate 25 mg oral tablets under&#x000a0;both brand and generic forms. Adult dosing for doxylamine is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>For insomnia (adults and children 12 and older): 25 to 50 mg orally at bedtime as needed, dosed 30 minutes before sleep.<xref ref-type="bibr" rid="article-37101.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>For allergy symptoms (adults and children 12 and older): 12.5 mg orally every 4 to 6 hours as needed, with a maximum dosage of 75 mg daily.</p>
          </list-item>
        </list>
        <p>Hepatic and renal dosing adjustments are not defined.</p>
      </sec>
      <sec id="article-37101.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Because doxylamine is available over the counter, the risk of overdose is a concern.<xref ref-type="bibr" rid="article-37101.r4">[4]</xref>&#x000a0;Adverse effects due to hypersensitivity to the drug include hypotension, urticaria, and decreased oxygen saturation.<xref ref-type="bibr" rid="article-37101.r15">[15]</xref> Common adverse effects&#x000a0;include&#x000a0;impaired vigilance, atropine-like effects, impaired coordination, and drowsiness during the day&#x02014;all of which could pose problems&#x000a0;for high-risk fall patients and those operating heavy machinery or who drive a vehicle.<xref ref-type="bibr" rid="article-37101.r16">[16]</xref>&#x000a0;</p>
        <p>Other common reactions to doxylamine include constipation, dysuria, urinary retention, blurred vision, and diplopia. Many of these can be attributed to the drug's anticholinergic effects.</p>
        <p>Doxylamine and other first-generation histamine H1 receptor antagonists can bind to and inhibit muscarinic receptor signaling in other&#x000a0;organ systems, resulting in systemic anticholinergic effects. This non-selective receptor binding can lead to various adverse effects such as&#x000a0;flushing of the skin, anhidrosis, hyperthermia, hallucinations, mydriasis, delirium, and urinary retention.<xref ref-type="bibr" rid="article-37101.r17">[17]</xref>&#x000a0;</p>
        <p>Doxylamine is safe for use in breastfeeding in small, occasional doses. No known fetal harm exists based on human data when it was studied in combination therapy with pyridoxine. In longer-term or higher doses, doxylamine might decrease lactation, and it could cause drowsiness or other adverse effects on the breastfed infant.<xref ref-type="bibr" rid="article-37101.r18">[18]</xref> Doxylamine is safe for use in pregnancy as it is not teratogenic.<xref ref-type="bibr" rid="article-37101.r3">[3]</xref></p>
      </sec>
      <sec id="article-37101.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>One contraindication to treatment with doxylamine includes&#x000a0;concurrent use of a monoamine oxidase inhibitor (MAOI).<xref ref-type="bibr" rid="article-37101.r13">[13]</xref> Hypersensitivity to doxylamine is also a contraindication to its use.<xref ref-type="bibr" rid="article-37101.r15">[15]</xref>&#x000a0;Concomitant&#x000a0;alcohol use is contraindicated due to its effect of causing pronounced somnolence when combined with doxylamine. It should&#x000a0;be used with caution when given concurrently with CNS depressant drugs. Doxylamine contraindications also include patients with the following conditions:&#x000a0;elevated intraocular pressure, narrow-angle glaucoma, asthma, stenosing peptic ulcer disease, urinary bladder neck obstruction, and gastric outlet obstruction.<xref ref-type="bibr" rid="article-37101.r11">[11]</xref></p>
        <p>Doxylamine should not be used in children under two years of age.</p>
      </sec>
      <sec id="article-37101.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Researchers have mostly studied the pharmacokinetics of doxylamine&#x000a0;in healthy nonpregnant women.&#x000a0;Doxylamine is&#x000a0;absorbed in the gastrointestinal tract, mainly the jejunum. With extended-release&#x000a0;formulation, peak plasma concentrations occur&#x000a0;within 7.5 hours.<xref ref-type="bibr" rid="article-37101.r13">[13]</xref>&#x000a0;Doxylamine is highly lipophilic; therefore, it circulates as 98% protein-bound. The volume of distribution is between 0.5&#x000a0;and 30 L/kg. Doxylamine undergoes hepatic metabolism via a dealkylation reaction, so the clinician should consider the patient's liver function.<xref ref-type="bibr" rid="article-37101.r17">[17]</xref>&#x000a0;Additionally, doxylamine and its respective metabolites get excreted by the kidneys, so clinicians should consider the patient's renal function when administering this drug. The half-life of doxylamine is 11.9 hours, and the half-life of coadministered pyridoxine is 0.4 hours.<xref ref-type="bibr" rid="article-37101.r11">[11]</xref></p>
      </sec>
      <sec id="article-37101.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Toxicity associated with antihistamine use is&#x000a0;due to overdose following oral ingestion, either unintentional or intentional suicide attempt&#x02014;most commonly in young and elderly populations. Toxicity from intravenous, intramuscular, or topical routes of administration rarely occurs in the household setting. Toxicity presents as antimuscarinic and hallucinogenic effects. The mnemonic 'dry as a bone, hot as a hare,&#x000a0;red as a beet, blind as a bat, full as a flask, and mad as a hatter' has been used to remember the presentation of acute anticholinergic toxicity. This mnemonic represents the findings of anhidrosis, hyperthermia, reddening of the skin, mydriasis, hallucinations, urinary retention, and delirium, respectively.</p>
        <p>Major complications of doxylamine toxicity include arrhythmias, respiratory failure, seizures, hyperthermia, rhabdomyolysis, and coma. If the&#x000a0;patient experiences toxicity, the healthcare team should continually monitor cardiac activity, and IV access is necessary. Patients who only recently ingested the toxic dose can receive activated charcoal.<xref ref-type="bibr" rid="article-37101.r17">[17]</xref><xref ref-type="bibr" rid="article-37101.r19">[19]</xref></p>
      </sec>
      <sec id="article-37101.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Doxylamine is available both over-the-counter and through a consultation with a physician. It&#x000a0;is a first-generation histamine H1 receptor antagonist that can lead to various&#x000a0;adverse outcomes if consumed inappropriately. Over-the-counter availability of doxylamine to consumers demands the&#x000a0;need to&#x000a0;educate patients and the general public on appropriate antihistamine consumption and&#x000a0;how to recognize signs of toxicity. Individuals taking doxylamine should understand the potential adverse effects and should receive instruction to store this medication in a secure location&#x000a0;where&#x000a0;children or other individuals at risk of ingesting a toxic dose (intentionally or unintentionally) cannot access it. Patients should also be counseled on the potential drug interactions with doxylamine, such as increased somnolence and sedation when consumed with alcohol or other central nervous system depressants because of cumulative effects.&#x000a0;</p>
        <p>An interprofessional healthcare team, including clinicians (MDs, DOs, NPS, and PAs), should be well-versed in recognizing the symptoms of doxylamine toxicity. They should be aware of the potential complications that can manifest, such as multiorgan failure and coma. Although most patients experience a full recovery following doxylamine toxicity, it is still vital that healthcare teams are knowledgeable and up to date on the presentation of doxylamine toxicity.<xref ref-type="bibr" rid="article-37101.r17">[17]</xref>&#x000a0;The prescribing clinician,&#x000a0;along&#x000a0;with a pharmacist, should&#x000a0;educate&#x000a0;the patient regarding dosing and interactions. The pharmacist (as well as nursing) can counsel the patient on administration and potential adverse effects. Nursing can also perform follow-up monitoring and also act as a bridge between the prescriber and the patient. If any one member of the interprofessional team notes an adverse event or therapeutic failure, it should be documented in the patient's health record and communicated to all other team members so appropriate action can take place. These examples of interprofessional collaboration show how to optimize doxylamine therapy for the best clinical results with the fewest adverse events. [Level 5]</p>
        <p>Historically, there has been significant debate around&#x000a0;a&#x000a0;reported correlation between using a combination product containing doxylamine and pyridoxine in the 1970s and congenital disabilities. Media and law firms launched publicity campaigns against the older formulation, which eventually resulted in the discontinuation of the drug for decades until&#x000a0;the newer formulation&#x000a0;received approval in 2013 for treating NVP refractory to other nonpharmacological management. Approval of the newer formulation was based on randomized, placebo-controlled clinical trials supporting its efficacy and safety.&#x000a0;It also considered&#x000a0;extensive data concluding that combined treatment with doxylamine succinate and pyridoxine hydrochloride in pregnancy is not teratogenic. This decades-long debate and evidence reinforce&#x000a0;the importance of evidence-based medicine.&#x000a0;</p>
        <p>In summary, doxylamine is a generally safe, effective over-the-counter medication that can provide patient benefit with minimal adverse events when used correctly.</p>
      </sec>
      <sec id="article-37101.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37101&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37101">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37101/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37101">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37101.s11">
        <title>References</title>
        <ref id="article-37101.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Persaud</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Should doxylamine-pyridoxine be used for nausea and vomiting of pregnancy?</article-title>
            <source>J Obstet Gynaecol Can</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>343</fpage>
            <page-range>343-348</page-range>
            <pub-id pub-id-type="pmid">24798673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Safety considerations surrounding use of treatment options for nausea and vomiting in pregnancy.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>1227</fpage>
            <page-range>1227-1234</page-range>
            <pub-id pub-id-type="pmid">28749713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fejzo</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Trovik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grooten</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Sridharan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Roseboom</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Vikanes</surname>
                <given-names>&#x000c5;</given-names>
              </name>
              <name>
                <surname>Painter</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Mullin</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Nausea and vomiting of pregnancy and hyperemesis gravidarum.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2019</year>
            <month>Sep</month>
            <day>12</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>62</fpage>
            <pub-id pub-id-type="pmid">31515515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derin&#x000f6;z-G&#x000fc;lery&#x000fc;z</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Doxylamine succinate overdose: Slurred speech and visual hallucination.</article-title>
            <source>Turk J Pediatr</source>
            <year>2018</year>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>439</fpage>
            <page-range>439-442</page-range>
            <pub-id pub-id-type="pmid">30859772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kakli</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>TD</given-names>
              </name>
            </person-group>
            <article-title>Allergic Rhinitis.</article-title>
            <source>Prim Care</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>465</fpage>
            <page-range>465-75</page-range>
            <pub-id pub-id-type="pmid">27545735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allison</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A Phase I Study of the Pharmacokinetics and Pharmacodynamics of Intranasal Doxylamine in Subjects with Chronic Intermittent Sleep Impairment.</article-title>
            <source>Drugs R D</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-136</page-range>
            <pub-id pub-id-type="pmid">29671128</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buysse</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Insomnia.</article-title>
            <source>JAMA</source>
            <year>2013</year>
            <month>Feb</month>
            <day>20</day>
            <volume>309</volume>
            <issue>7</issue>
            <fpage>706</fpage>
            <page-range>706-16</page-range>
            <pub-id pub-id-type="pmid">23423416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shiroishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Structural Analysis of the Histamine H<sub>1</sub> Receptor.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2017</year>
            <volume>241</volume>
            <fpage>21</fpage>
            <page-range>21-30</page-range>
            <pub-id pub-id-type="pmid">27826702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simons</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Simons</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>H1 antihistamines: current status and future directions.</article-title>
            <source>World Allergy Organ J</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>1</volume>
            <issue>9</issue>
            <fpage>145</fpage>
            <page-range>145-55</page-range>
            <pub-id pub-id-type="pmid">23282578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madjunkova</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maltepe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The delayed-release combination of doxylamine and pyridoxine (Diclegis&#x000ae;/Diclectin &#x000ae;) for the treatment of nausea and vomiting of pregnancy.</article-title>
            <source>Paediatr Drugs</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>199</fpage>
            <page-range>199-211</page-range>
            <pub-id pub-id-type="pmid">24574047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mospan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mospan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Byland</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Whitaker</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Xiong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dunlap</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Canupp</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Drug updates and approvals: 2018 in review.</article-title>
            <source>Nurse Pract</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>43</volume>
            <issue>12</issue>
            <fpage>23</fpage>
            <page-range>23-32</page-range>
            <pub-id pub-id-type="pmid">30379711</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fantasia</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>A new pharmacologic treatment for nausea and vomiting of pregnancy.</article-title>
            <source>Nurs Womens Health</source>
            <year>2014</year>
            <season>Feb-Mar</season>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-77</page-range>
            <pub-id pub-id-type="pmid">24548499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cada</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Demaris</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Levien</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Doxylamine succinate/pyridoxine hydrochloride.</article-title>
            <source>Hosp Pharm</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>48</volume>
            <issue>9</issue>
            <fpage>762</fpage>
            <page-range>762-6</page-range>
            <pub-id pub-id-type="pmid">24421551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <article-title>Drugs for chronic insomnia.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2018</year>
            <month>Dec</month>
            <day>17</day>
            <volume>60</volume>
            <issue>1562</issue>
            <fpage>201</fpage>
            <page-range>201-205</page-range>
            <pub-id pub-id-type="pmid">30625122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rial</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Nieto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodrigo-Mu&#x000f1;oz</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sastre</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sastre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Del Pozo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Doxylamine Allergy in a Pregnant Woman: Suitability of the Basophil Activation Test.</article-title>
            <source>J Investig Allergol Clin Immunol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>433</fpage>
            <page-range>433-434</page-range>
            <pub-id pub-id-type="pmid">30530395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <article-title>Sleep complaints: Whenever possible, avoid the use of sleeping pills.</article-title>
            <source>Prescrire Int</source>
            <year>2008</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>97</issue>
            <fpage>206</fpage>
            <page-range>206-12</page-range>
            <pub-id pub-id-type="pmid">19536941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r17">
          <label>17</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Borowy</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Mukherji</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Antihistamine Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">29493943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r18">
          <label>18</label>
          <element-citation publication-type="book">
            <chapter-title>Doxylamine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>9</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">29999680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37101.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doshi</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Giudici</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>The EKG in hypothermia and hyperthermia.</article-title>
            <source>J Electrocardiol</source>
            <year>2015</year>
            <season>Mar-Apr</season>
            <volume>48</volume>
            <issue>2</issue>
            <fpage>203</fpage>
            <page-range>203-9</page-range>
            <pub-id pub-id-type="pmid">25537312</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
